30 results about "Diflunisal" patented technology

The administration to a mammal of a combination of compounds, at least one of which is an a2d calcium channel subunit (A2d) ligand and at least one of which is a non-steroidal anti-inflammatory drug (NSAID), provides a surprising and potent inhibition of the micturition reflex, superior to that obtained by treatment with an A2d ligand or NSAID alone. Combinations of A2d ligand and NSAIDs are thus useful for treatment of lower urinary tract disorders and symptoms thereof. Preferred A2d ligands are gabapentin and pregabalin. Preferred NSAIDs are celecoxib, diclofenac, diflunisal, flurbiprofen, naproxen, nimesulide or sulindac.

O-medium alkyl esters of diflunisal and related compounds are disclosed having anti-platelet activity, hydroxy radical scavenging properties, enhanced hepatic clearance and low ulcerogenic potential. These compounds have general formula (I) wherein n equals 3-13.

This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier. The combinations and compositions of this invention are useful as methods for treating metabolic disorders including diabetes, particularly Type I and Type II diabetes, as well as diseases and disorders associated with diabetes, including but not limited to atherosclerosis, cardiovascular disease, inflammatory disorders, nephropathy, neuropathy, retinopathy, β-cell dysfunction, dyslipidemia, LADA, metabolic syndrome, hyperglycemia, insulin resistance, and / or chronic obstructive pulmonary disease in a mammal, particularly a diabetic mammal, and specifically a human patient. This invention is particularly directed to pharmaceutical compositions comprising an lipoic acid, one or more anti-inflammatories selected from the group consisting of diflunisal, diclofenac, dexibuprofen, dexketoprofen, naproxen, and salicylate, and optionally one or more pharmaceutically acceptable carriers. The compositions of this invention are useful as methods for treating metabolic disorders including type II diabetes, insulin resistance, beta-cell dysfunction, and hyperglycemia in a patient, particularly a diabetic patient.

The invention discloses a diflunisal solid dispersion and a preparation method thereof. The solid dispersion is composed of diflunisal as active components and high-polymer carrier materials. The high-polymer carrier materials are 40-90% of the diflunisal in total and selected from povidones, copovidones, and polyethylene glycol / vinyl caprolactam / vinyl acetate copolymer or hydroxypropyl methylcellulose. The preparation method adopts a hot-melting extrusion method. The diflunisal solid dispersion obtained is higher in solubility and quick and high in dissolving, bioavailability of indissolvable drugs is improved, drug dosage is reduced, and adverse drug reaction is reduced.

The invention discloses a method for synthetizing diflunisal and a derivative thereof through a one-step method. The method comprises the steps: under joint catalysis of an iron salt, a ligand and titanate, 2,4-difluorophenylmagnesium halide and 5-halogenated salicylic acid or a 5-halogenated salicylic acid derivative are mixed, heated and coupled in a solvent, and the diflunisal and the derivative thereof are obtained. The method has the advantages that (1) high-priced palladium or high-toxicity nickel does not need to be adopted as catalytic metal, only low-toxicity, high-yield and inexpensive iron salts and titanate need to be used, thus the cost is low, and environmental friendliness is achieved; (2) a zinc salt does not need to be used, or step preparation of a boron reagent is not needed, a Grignard reagent is directly used, the preparation steps are few, and raw material and energy consumption is low; and (3) operation is easy and convenient, conditions are mild, amplification is easy, and the method is suitable for industrial production.

The present invention provides a fluorine benzene ruthenium compound and a preparation method and application thereof. The structure of the fluorine benzene ruthenium compound is shown in formula (I). The fluorine benzene ruthenium compound is synthesized and generated by dichloridized dichloro-2-methyl-isopropyl-benzo dirhodium and phenylacetyl diflunisal and shows a relatively strong inhibition activity on a human lymph cancer cell strain and a liver cancer strain of a human body. The fluorine benzene ruthenium compound can be used for preparing medicines for treating liver cancer and lymph cancer, and can be prepared to injections, tablets, pellets, capsules, suspensions or emulsions. The fluorine benzene ruthenium compound provided by the invention can improve the lipid solubility and the permeability of medicines, enhances the dissolubility of a biological film and prompts the speed of absorption and transmission in vivo, so that the physiological action changes.

The present invention relates to design and synthesis of a novel prodrug of diflunisal, salsalate, and salicylic acid, wherein the prodrug is positively charged, and has a structural formula 1 as shown in the general formula (1), and a structural formula 2 as shown in the general formula (2). The compound with the structural formula 1 as shown in the general formula (1), and the structural formula 2 as shown in the general formula (2) can be prepared by a reaction of diflunisal, salsalate and salicylic acid with appropriate alcohol, mercaptan, or amine. The prodrugs can be used in medicine for the therapy of humans or animals in a state that can be treated with diflunisal, salsalate, or salicylic acid, and in the therapy process, the prodrugs can be orally used, and can be transdermally administrated, so that the most side effects of the diflunisal, salsalate, or salicylic acid are avoided. According to a controlled release transdermal administration system of the prodrug, the concentration of the diflunisal, salsalate, or salicylic acid in blood can be kept stable in the optimal therapy proficiency, so that the efficacy is improved, and the side effects of the diflunisal, salsalate, or salicylic acid are reduced.

The invention relates to a self-assembly system based on hydrophilic polymer and medicine and a preparation method thereof. The system consists of a hydrophilic polymer and a carboxyl-containing medicine, wherein the hydrophilic polymer is polymine or beta-cyclodextrin modified polymine; and the carboxyl-containing medicine is selected from ibuprofen, ketoprofen, fenoprofen, flurbiprofene, oxaprozin, naproxen, indometacin, sulindac, etodolac, diclofenac, pontal, meclofenamic acid, flufenamic acid, tolfenamic acid, lumiracoxib, licofelone, diflunisal and aspirin. The system is prepared by dissolving the hydrophilic polymer in a certain amount of water, dissolving the medicine in a water soluble solvent, slowly adding the organic solution of the medicine into the aqueous solution of the polymer under the action of ultrasound, placing the mixed solution in a dialysis bag, dialyzing in deionized water with magnetic stirring, replacing the deionized water at certain time interval, filtering dislysate after 5 to 48 hours, cooling and drying.